We are ready and looking forward to seeing you! With three abstracts presented and approved, our participation at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting highlights Quibim’s strong commitment to further transform #healthcare through innovative #imagingsolutions. In words of our Co-founder and CEO, Dr Ángel Alberich-Bayarri, "We are acutely aware of the real-life impact our products are having, which is why we’re always striving to expand and enhance our products in line with scientific and health industry advancements and we look forward to sharing our latest findings with the ASCO attendees”. All about our presence at #ASCO2024 here ➡ https://bit.ly/44J2sB5
Explore our latest blog, “From Images to Insights: Quantitative PSMA-PET coupled with AI in prostate cancer clinical trials.” This post discusses the transformative role of PSMA (prostate-specific membrane antigen) in diagnosing and treating #ProstateCancer. Learn how we have utilized the potential of PSMA to convert biomarkers into meaningful predictions as our #AI-driven solutions offer unparalleled accuracy in evaluating treatment effectiveness and forecasting patient outcomes. Key highlights: 🔹 Increased diagnostic accuracy with PSMA-PET. 🔹 Advanced segmentation and image biomarker extraction. 🔹 AI solutions that predict metastatic risk, treatment response and more. Read the full post https://bit.ly/3R4F3nW, written by our Project Manager Sarah Vizel Genco, to discover how Quibim is setting a new standard in #clinicaltrials with PSMA-PET imaging.
With the endorsement of SERAM - Sociedad Española de Radiología Médica, we bring you our next webinar “Clinical case session: AI in #prostatecancer” the perfect chance to connect our shared enthusiasm for #radiology and the latest advances in diagnosis. Don't miss this opportunity to learn from the best in the industry with a unique presentation with real clinical cases. Speakers: Dr Kai Vilanova MD, PhD Dr Margarita Fontes 🗓️ Date: June 12 🕒 Time: 18:30 PM (CEST) / 13:30 PM (GMT-3) 📢 Language: Spanish Register now! https://bit.ly/3wSrNfo
"With [QP-Prostate], 10% more patients with hashtag#prostate carcinoma can be detected compared to conventional reading." - Dr Jerónimo Barrera, specialist in Radiodiagnosis at the Hospital Clínico San Carlos, Madrid. Read the full article to find out everything that this expert has to say about our flagship product ➡ https://bit.ly/3X1k6xY
🗓️ Today is the biannual meeting of the ProCanAid consortium, which takes place in Zaragoza, Spain. As the central coordinator, we are leading the project together with our partners from the Medical Research Institute La Fe (IIS La Fe) and Universidad de Zaragoza, who are committed to driving a transformative change in this field. A major milestone of this project is the development of a new model for automatic segmentation of neurovascular bundles. Scientific evidence shows that the involvement of neurovascular bundles is related to #ProstateCancer staging and clinical variables such as overall survival or the development of metastasis, and we are currently working and advancing on this model. To learn more in depth about the project and our involvement in it, do not miss the following video: https://bit.ly/3PHV4yi *Project PLEC2021-007709 funded by MCIN/AEI/10.13039/501100011033 and by Unión Europea NExtGenerationEU/PRTR
LATEST ANNOUNCEMENT! We are set to present pioneering research in #oncology with three accepted abstracts at the upcoming prestigious American Society of Clinical Oncology (ASCO) Annual Meeting. 1️⃣ Abstract #10054 - Dr. Ana Jimenez Pastor will present new machine-learning models that excel in predicting overall survival and facilitating risk stratification in neuroblastoma patients within the large, multi-institutional PRIMAGE cohort https://lnkd.in/eU2Nr6iG 2️⃣ Abstract #e20603 - Our research reviews and analyzes the application of AI-driven radiomics from CT scans to predict oncogene mutations in non-small cell lung cancer (NSCLC) https://lnkd.in/eKNrCyKu 3️⃣ Abstract #e20611 - We also study advances the use of deep learning features combined with radiomics to predict the response to immunotherapy in advanced NSCLC cases. https://lnkd.in/euxcDCgn Learn everything about our presence at #ASCO2024 ➡ https://bit.ly/44J2sB5
Thank you very much Odelle Technology and Steven Haken for having our CEO & Co-Founder, Dr Ángel Alberich-Bayarri in your podcast. A great opportunity to discuss what we do at Quibim and share our vision of improving #patientcare and #precisionmedicine.
We are delighted to showcase our latest radiology solutions at #SERAM24, in the beautiful city of Barcelona ⭐ Meet our team at booth 14 or visit us at the #AI corner. We will show you how to employ our AI-powered solutions to improve diagnostic accuracy and streamline clinical workflows. Who will we see these days at the CCIB? Don't hesitate to stop by and say hello 👋🏻 #Radiology #PrecisionMedicine
Live from Las Vegas, our team is full steam ahead at #ASNR24, exploring the vibrant world of neuroimaging alongside industry leaders and neuroradiologists from diverse backgrounds. 🧠 It's fantastic to contribute to the exciting discussions shaping the future of neuroradiology. This time, we proudly showcase our innovative brain MRI analysis solution, QP-Brain, which offers quantitative evaluations for improved detection and a more comprehensive understanding of brain atrophy and lesions. Are you currently in Las Vegas? We look forward to meeting you! 🙌🏻 #ASNR24 #Neuroradiology #PrecisionMedicine Jason Santos Néstor Jiménez American Society of Neuroradiology
On #ClinicalTrialsDay, we recognize the complex process a new drug goes through from conception to market distribution, a path that requires considerable resources and time. With an average timeline of 12 to 15 years, the process involves extensive research, meticulous testing and lengthy regulatory approvals. However, the drug development landscape is evolving, embracing the transformative potential of #AI. Tools based on #MachineLearning could further accelerate regulatory reviews and improve real-time patient monitoring via wearable devices, pushing the boundaries of efficient drug development. Among others, Quibim is developing an AI algorithm to interpret PET/CT scans, evaluating the efficacy of novel radiotracers targeting CD8 receptors in tumors. This innovation promises to improve immunotherapy response predictions and advance clinical development. Read our most recent blog post https://bit.ly/3QRZVyS, in which our CMO Glen Weiss, MD, MBA, explores how AI is streamlining workflows and reducing costs by transforming drug development and clinical trials.
